Propofol Manufacturer Ordered to Pay $365M in Nevada Hepatitis C Case, Plans Appeal
Teva, which was ordered to pay $365 million, said in a statement that the company clearly labeled the vials as single use and that aseptic procedures should be used at all times. The company believes there is enough evidence to warrant an appeal of the court's decision.
Baxter, which was ordered to pay $144 million, said it would also submit an appeal.
Mr. Chanin's case is the first of many to reach trial after a 2006 hepatitis C outbreak at Las Vegas endoscopy clinics. The $500 million award follows more than $5 million already awarded to Mr. Chanin and his wife by the same jury, according to the report.
Read the New York Times' report about the Las Vegas hepatitis C trial.
© Copyright ASC COMMUNICATIONS 2016. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
- Innovation in GI: Advances in gastroenterology technology & technique
- A game changer for GI — Dr. Anthony Starpoli on how the TIF procedure can control regurgitation
- How to create a strategic partnership with a hospital
- 9 states with the highest & lowest physician salaries
- Frenetic consolidation: The anesthesia market today & where ASCs fit in